W. Scott McDougal, MD, is a urologist at the Massachusetts General Hospital Department of Urology. He specializes in the treatment of cancer and related research.
1964 AB Dartmouth College, Hanover, New Hampshire, 1968 M.D. Cornell University Medical College, New York, New York, 1991 A.M. (Honorary) Harvard University, Boston, Massachusetts.
1968 - 1975 Resident in Urology and General Surgery,University Hospitals of Cleveland, Case-Western Reserve University Medical School. Renal Physiology, Yale Medical College.
Radiofrequency ablation of renal cell carcinoma. BJU Int 99:1271-2, 2007.>
Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology 74(4):708-12, 2008.
TIP30 is associated with progression and metastasis of prostate cancer. International J Cancer. 123(4):810-6, 2008.
Cavernous nerve regeneration using acellular nerve grafts. World J Urol.26(4):333-0.
Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 15(3):1024-31, 2009.
A prospective study of symptom distress and return to baseline function after open versus laparoscopic radical prostatectomy. J Urol. 182(3):956-65, 2009.
MGH Hotline 06.18.10 On the eve of the MGH bicentennial, one MGH department proudly celebrates its centennial.
In General awards and honors
THE MGH WILL WELCOME new chiefs for the Department of Neurology and the Department of Urology later this spring.
A team led by MGH researchers has identified a genetic signature that may reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer. If confirmed, the genetic risk index also may help distinguish tumors that require aggressive treatment from those that can safely be monitored.